Jun 2026 (Q2 FY26) — Aug 6, 2026
Lexicon Pharmaceuticals Q2 FY26 — SONATA-HCM Enrollment Complete, Zynquista NDA Resubmission Nears
Read the full callLexicon Pharmaceuticals (LXRX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Lexicon Pharmaceuticals earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.69 | −97.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -3835.3 | −3848.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -31.8 | −1077.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$1.65 +3.12% · +$0.05
Performance +13.0% 1Y
1Y: $1.46 on 14 Oct 2025 → $1.65. High $2.64 (29 Jun 2026), low $1.14 (2 Jan 2026).
- Previous close
- $1.6
- 52-week range
- $1.14 – $2.64
- One year
- +7.84%
Overview
- Symbol
- LXRX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Lexicon Pharmaceuticals earnings calls (LXRX)
Financials
What the filings say
Net profit, year on year: −1077% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 27 | 1 | 29 | 14 | 5 | 21 | 1 |
| Expenses | 65 | 59 | 27 | 25 | 26 | 20 | 22 | 27 |
| Operating profit | -64 | -33 | -26 | 4 | -12 | -15 | -1 | -27 |
| Operating margin | −3639.6% | −123.3% | −2034.8% | 12.9% | −85.9% | −269.1% | −4.7% | −3835.3% |
| Net profit | -65 | -34 | -25 | 3 | -13 | -16 | -1 | -32 |
| EPS ($ per share) | -0.18 | — | -0.07 | 0.01 | -0.04 | — | 0 | -0.07 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -1,472 | -1,341 | -1,400 | -1,488 | -1,590 | -1,767 | -1,967 | -2,018 |
| Total liabilities | 311 | 301 | 47 | 23 | 77 | 136 | 152 | 77 |
| Fixed assets | 16 | 14 | 0 | 1 | 2 | 2 | 2 | 2 |
| Investments | 80 | 236 | 26 | 23 | 92 | 148 | 171 | 62 |
| Total assets | 284 | 418 | 204 | 137 | 194 | 229 | 298 | 185 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -149 | 114 | -143 | -87 | -89 | -162 | -179 | -68 |
| Cash from investing | 170 | -156 | 381 | 2 | -71 | -50 | -15 | 113 |
| Cash from financing | -2 | -2 | -148 | 23 | 142 | 188 | 238 | -48 |
| Net cash flow | — | — | — | -62 | -18 | -24 | 44 | -3 |
| Capital expenditure | -0 | -0 | -0 | -1 | -1 | -0 | -1 | 0 |
| Free cash flow | -149 | 114 | -143 | -88 | -90 | -162 | -180 | -68 |
Insider filings
45 filings between Feb 2, 2026 and Jun 3, 2026.
Open market
decisions to buy or sellPurchases
$2.72M
8 purchases by 2 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 4
- Award — granted as compensation
- 25
- Option exercise — converted options into shares
- 8
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Invus Global Management, LLC | $2.00M | — | Feb 2, 2026 |
| DEBBANE RAYMOND | $722.6K | — | Feb 25, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 3, 2026 | DEBBANE RAYMOND Director | Option exercise | 89,312 | $0 |
| Jun 3, 2026 | Amouyal Philippe Director | Option exercise | 89,312 | $0 |
| Jun 3, 2026 | BARKER SAM L Director | Option exercise | 89,312 | $0 |
| Jun 3, 2026 | Cheung Ivan Director | Option exercise | 89,312 | $0 |
| Jun 3, 2026 | SOBECKI CHRISTOPHER J Director | Option exercise | 89,312 | $0 |
| Jun 3, 2026 | Sullivan Diane E. Director | Option exercise | 89,312 | $0 |
| Jun 3, 2026 | Swain Judith L Director | Option exercise | 89,312 | $0 |
| Apr 30, 2026 | Artal Participations S.a r.l. Director | Option exercise | 20,421,735 | $0 |
| Feb 28, 2026 | Exton Michael Chief Executive Officer | Option exercise | 503,263 | — |
| Feb 28, 2026 | Exton Michael Chief Executive Officer | Tax withheld | 204,831 | $301.1K |
| Feb 28, 2026 | Coiante Scott M SVP, Chief Financial Officer | Option exercise | 160,237 | — |
| Feb 28, 2026 | Coiante Scott M SVP, Chief Financial Officer | Tax withheld | 54,881 | $80.7K |
| Feb 28, 2026 | Crum Brian T SVP, General Counsel & Secr. | Option exercise | 33,457 | — |
| Feb 28, 2026 | Crum Brian T SVP, General Counsel & Secr. | Option exercise | 69,386 | — |
| Feb 28, 2026 | Crum Brian T SVP, General Counsel & Secr. | Option exercise | 170,163 | — |
| Feb 28, 2026 | Crum Brian T SVP, General Counsel & Secr. | Tax withheld | 105,019 | $154.4K |
| Feb 28, 2026 | DeFrancesco Lisa SVP, IR and Corp Comm | Option exercise | 24,674 | — |
| Feb 28, 2026 | DeFrancesco Lisa SVP, IR and Corp Comm | Option exercise | 128,190 | — |
| Feb 28, 2026 | DeFrancesco Lisa SVP, IR and Corp Comm | Tax withheld | 74,572 | $109.6K |
| Feb 28, 2026 | Gopinathan Suma SVP, Discovery | Option exercise | 14,000 | — |
| Feb 28, 2026 | Gopinathan Suma SVP, Discovery | Option exercise | 20,310 | — |
| Feb 28, 2026 | Gopinathan Suma SVP, Discovery | Option exercise | 65,640 | — |
| Feb 28, 2026 | Gopinathan Suma SVP, Discovery | Tax withheld | 24,338 | $35.8K |
| Feb 28, 2026 | Granowitz Craig B SVP, Chief Medical Officer | Option exercise | 35,790 | — |
| Feb 28, 2026 | Granowitz Craig B SVP, Chief Medical Officer | Option exercise | 74,226 | — |
| Feb 28, 2026 | Granowitz Craig B SVP, Chief Medical Officer | Option exercise | 202,260 | — |
| Feb 28, 2026 | Granowitz Craig B SVP, Chief Medical Officer | Tax withheld | 109,098 | $160.4K |
| Feb 28, 2026 | Martens Rachel Yap SVP, Partnerships & Corp Strat | Option exercise | 67,090 | — |
| Feb 28, 2026 | Martens Rachel Yap SVP, Partnerships & Corp Strat | Tax withheld | 35,826 | $52.7K |
| Feb 28, 2026 | McDermott Wendy SVP, Human Resources | Option exercise | 27,697 | — |
| Feb 28, 2026 | McDermott Wendy SVP, Human Resources | Option exercise | 52,316 | — |
| Feb 28, 2026 | McDermott Wendy SVP, Human Resources | Option exercise | 144,393 | — |
| Feb 28, 2026 | McDermott Wendy SVP, Human Resources | Tax withheld | 68,107 | $100.1K |
| Feb 25, 2026 | DEBBANE RAYMOND Director | Purchase | 2,000 | $3.0K |
| Feb 23, 2026 | DEBBANE RAYMOND Director | Purchase | 100,000 | $147.0K |
| Feb 20, 2026 | DEBBANE RAYMOND Director | Purchase | 100,000 | $147.8K |
| Feb 19, 2026 | DEBBANE RAYMOND Director | Purchase | 50,000 | $72.0K |
| Feb 18, 2026 | DEBBANE RAYMOND Director | Purchase | 133,688 | $176.5K |
| Feb 17, 2026 | Artal Participations S.a r.l. Director | Award | 41,290 | $2.68M |
| Feb 17, 2026 | DEBBANE RAYMOND Director | Purchase | 76,857 | $100.5K |
| Feb 13, 2026 | DEBBANE RAYMOND Director | Purchase | 57,952 | $75.9K |
| Feb 2, 2026 | Invus Global Management, LLC Director | Award | 367,145 | $23.86M |
| Feb 2, 2026 | Invus Global Management, LLC Director | Award | 18,553,846 | $24.12M |
| Feb 2, 2026 | Invus Global Management, LLC Director | Award | 3,846,154 | $5.00M |
| Feb 2, 2026 | Invus Global Management, LLC Director | Purchase | 1,538,462 | $2.00M |
| May 13, 2025 | DEBBANE RAYMOND Director | Option exercise | 36,810 | $0 |
| May 13, 2025 | SOBECKI CHRISTOPHER J Director | Option exercise | 36,810 | $0 |
| May 13, 2025 | Sullivan Diane E. Director | Option exercise | 36,810 | $0 |
| May 13, 2025 | Swain Judith L Director | Option exercise | 36,810 | $0 |
| May 13, 2025 | Amouyal Philippe Director | Option exercise | 36,810 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for LEXICON PHARMACEUTICALS, INC.
Free account. Everything above stays public.
Write why you follow LEXICON PHARMACEUTICALS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading